Anlotinib (AL3818) plus pemetrexed in patients with recurrent platinum-resistant advanced epithelial ovarian cancer: A single-arm, open-label, phase II study.

被引：0
|
作者：
Zhang, Yanna
Chen, Jueming
Wei, Wei
Zheng, Lie
Li, Han
Feng, Yanling
Wan, Ting
Qiu, Jiaqi
Jiang, Xingyu
Xiong, Ying
Li, Jundong
Song, Libing
Liu, Jihong
Huang, He
机构：
[1] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Gynecol Oncol, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Imaging, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China
[3] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Biotherapy, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China
[4] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Expt Res, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China
[5] Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, Dept Med Oncol,State Key Lab Oncol South China, Guangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18078
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Anlotinib plus pemetrexed in patients with platinum-resistant ovarian cancer: A single-arm, open-label, phase II study
    Chen, J.
    Wei, W.
    Zheng, L.
    Li, H.
    Feng, Y.
    Wan, T.
    Huang, Q.
    Liu, G.
    Tu, H.
    Qiu, J.
    Jiang, X.
    Xiong, Y.
    Zheng, M.
    Li, J.
    Huang, H.
    Song, L.
    Liu, J.
    Zhang, Y.
    ANNALS OF ONCOLOGY, 2021, 32 : S734 - S734
  • [2] Anlotinib plus pemetrexed as a further treatment for patients with platinum-resistant ovarian cancer: A single-arm, open-label, phase II study.
    Chen, Jueming
    Wei, Wei
    Zheng, Lie
    Li, Han
    Feng, Yanling
    Wan, Ting
    Qiu, Jiaqi
    Jiang, Xingyu
    Xiong, Ying
    Zheng, Min
    Li, Jundong
    Huang, He
    Song, Libing
    Liu, Jihong
    Zhang, Yanna
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [3] Anlotinib plus letrozole in patients with platinum-resistant recurrent ovarian cancer: A prospective, single-arm, open-label, phase II study.
    Wang, Xipeng
    Li, Jiarui
    Zhang, Ping
    Fang, Xuhong
    Wang, Yizhi
    Sun, Huizhen
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E17545 - E17545
  • [4] Anlotinib plus hormone therapy in patients with platinum-resistant recurrent ovarian cancer: A prospective, single-arm, open-label, phase II study
    Wang, Xipeng
    Li, Jiarui
    Zhang, Ping
    Wang, Yizhi
    Lu, Xin
    Xu, Hong
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] Anlotinib combined with pemetrexed as a further treatment of patients with platinum-resistant ovarian cancer: A single-arm, open-label, phase II study
    Gaillard, Stephanie
    Duska, Linda
    Broadwater, Gloria
    McNally, Leah
    Lee, Paula
    Davidson, Brittany
    Previs, Rebecca
    Moss, Haley
    Berchuck, Andrew
    Nixon, Andrew
    Yi, John
    Bookman, Michael
    Secord, Angeles Alvarez
    GYNECOLOGIC ONCOLOGY, 2021, 162 : S61 - S62
  • [6] Phase II study of anlotinib plus pemetrexed for platinum-resistant epithelial ovarian cancer
    Chen, J.
    Wei, W.
    Zheng, L.
    Li, H.
    Feng, Y.
    Wan, T.
    Qiu, J.
    Jiang, X.
    Xiong, Y.
    Li, J.
    Huang, H.
    Song, L.
    Liu, J.
    Zhang, Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S630 - S631
  • [7] Anlotinib in patients with recurrent platinum-resistant or refractory ovarian carcinoma: A prospective, single-arm, single-center, phase II clinical study.
    Wang, Huaying
    Shen, Wenbin
    Shan, Boer
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] Anlotinib in patients with recurrent platinum-resistant or refractory ovarian carcinoma: A prospective, single-arm, single-center, phase II clinical study.
    Shan, Boer
    Shen, Wenbin
    Wang, Huaying
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [9] Anlotinib plus sintilimab in patients with recurrent advanced endometrial cancer: A prospective open-label, single-arm, phase II clinical trial
    Wei, W.
    Ban, X.
    Yang, F.
    Huang, Y.
    Li, J.
    Cheng, X.
    Zheng, M.
    Li, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S762 - S762
  • [10] Anlotinib in Chinese Patients With Recurrent Advanced Cervical Cancer: A Prospective Single-Arm, Open-Label Phase II Trial
    Zhu, Jun
    Song, Chunyan
    Zheng, Zhong
    Xia, Lingfang
    Chen, Yanqiong
    Ke, Guihao
    Wu, Xiaohua
    FRONTIERS IN ONCOLOGY, 2021, 11
12345